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Purpose: Dermatofibrosarcoma protuberans (DFSP) carries a translocation result-
ing in the collagen type I alpha 1 (COL1A1)-platelet-derived growth factor beta 
(PDGFB) fusion gene, which is responsible for PDGFB activation. The purpose 
of this study is to evaluate the clinicopathological, genetic, and therapeutic features 
of DFSP in Korean patients. Materials and Methods: Clinicopathological fea-
tures of 37 patients with DFSP were reviewed. Multiplex reverse transcriptase-
polymerase chain reaction (PCR) was carried out in 16 patients using formalin-
fixed, paraffin-embedded tissues and specific primers for COL1A1 and PDGFB. 
Results: The mean age of 37 patients was 37.4 years old. The most common tumor 
location was the trunk. All patients were treated primarily with surgery: 34 (91.7%) 
cases with Mohs micrographic surgery (MMS) and 3 (8.3%) cases with wide local 
excision. The median follow-up time was 33.7 months. Two patients, one in each 
treatment group, demonstrated local recurrence during the follow-up period. The 
COL1A1-PDGFB fusion gene was expressed in 14 (87.5%) cases, demonstrated 
by reverse transcriptase PCR analysis. No association was found among the differ-
ent COL1A1-PDGFB fusion transcripts, the various histological subtypes and 
clinical features. Conclusion: Our results support the effectiveness of MMS in 
treating DFSP. The COL1A1-PDGFB fusion transcript was observed in 87.5% of 
patients. Therefore, COL1A1-PDGFB is a useful and accurate tool in diagnosing 
DFSP in Koreans.
Key Words:   Dermatofibrosarcoma protuberans, collagen type I alpha 1-platelet-
derived growth factor beta, histological subtype, Mohs micrographic 
surgery
INTRODUCTION
Dermatofibrosarcoma protuberans (DFSP) is a sarcomatous tumor of the cutane-
ous tissue first described by Taylor in 1890.1 It is an uncommon infiltrative dermal 
and subcutaneous tumor characterized by progressive local growth of CD34+ 
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rence and any subsequent procedures were collected and 
compiled. 
All patients were treated by one of the two surgeons. Pa-
tients were treated by WLE or standard MMS using the 
fresh frozen tissue technique. WLE was performed with a 
2-cm margin. For MMS, the visible border of each lesion 
was demarcated, and a 5-mm margin was drawn around 
each lesion’s clinical edge. In cases of recurrence, scars were 
removed en bloc with the recurrent tumor before the MMS 
layer was excised to identify any residual tumor around the 
scar tissue. Afterwards, the tissue sections were placed in 
cassettes and submitted with the MMS map for pathologi-
cal examination. If any evidence of tumor was seen within 
the specimen, further tissue removal was performed. Addi-
tional 5-mm-thick layer of tissue was removed after careful 
mapping of the positive margin, and this layer was patho-
logically examined as described above. This process was 
repeated until all margins were cleared. All sections were 
embedded in paraffin wax for later confirmation by haema-
toxylin and eosin (H&E) staining, and CD34 staining was 
also used in suspicious cases. For all patients, the central 
bulk of the tumor was sent to the pathology laboratory to 
have permanent sections taken to confirm the diagnosis of 
DFSP. All patients underwent primary reconstruction by the 
two surgeons.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embed-
ded archival tissue with antibodies against CD34 (1:50; 
BioGenex, San Ramon, CA, USA), p53 (1:50; Dako, Car-
pinteria, CA, USA), and Ki-67 (1:50; Dako, Carpinteria, 
CA, USA). Appropriate positive and negative controls were 
run in parallel. Immunostaining was evaluated separately 
by two authors. Quantification of the immunohistochemis-
try marker CD34 was based on the percentage of immuno-
reactive cells as follows: high (≥50%) or low (<50%). The 
immunohistochemical quantification of nuclear markers was 
evaluated as follows: positive (>5% immunoreactive nuclei) 
or negative (<5%).
Identification of COL1A1-PDGFB fusion transcripts
Total RNA was extracted from formalin-fixed, paraffin-em-
bedded tissue blocks using an RNeasy Mini Kit (QIAGEN, 
Hilden, Germany) and reverse-transcribed using a Super-
script Preamplification System (Gibco-BRL, Gaithersburg, 
MD, USA). To detect the expression of the PDGFB gene, 
first-strand cDNA was amplified with the AGexpdgf3 and 
spindle cells with a highly infiltrative pattern.2 Surgical ex-
cision is the main treatment modality; however, local recur-
rence rates after conservative surgical resection have been 
reported to be 26% to 60%.3,4 Although wide local excision 
(WLE) has been shown to further reduce the recurrence 
rate to 0% to 30%,2-7 several reports indicate that Mohs mi-
crographic surgery (MMS) results in a lower overall recur-
rence rate (0‒8%) compared with WLE.7,8 
Cytogenetically, DFSP carries a rearrangement of chro-
mosomes 17 and 22, which results in formation of the colla-
gen type I alpha 1 (COL1A1)-platelet-derived growth factor 
beta (PDGFB) fusion gene.9 This gene codes for a fusion 
protein that overlaps functionally with the mature form of 
PDGFB.10 It activates PDGFB receptor (PDGFBR), and 
thus accelerates DFSP growth through an autocrine-para-
crine loop. Based on this knowledge, imatinib mesylate has 
been used to treat patients with inoperable DFSP, and has 
shown impressive clinical results.9 We previously reported 
11 patients with DFSP who were successfully treated by 
MMS,8 and the purpose of our present study is to evaluate 
the clinicopathological, genetic (COL1A1-PDGFB), and 
therapeutic features of DFSP in 37 Korean patients.
MATERIALS AND METHODS
Case selection and clinicopathological data
All cases of DFSP included in the pathological database of 
Yonsei University Health System in Seoul, Korea from 
1997 to 2012 were reviewed. Informed consent was ob-
tained in accordance with the ethical committee procedures 
of the institution (IRB No. 4-2011-0659). The following 
clinical data were recorded: age, gender, tumor location, tu-
mor size (centimeters), tumor type (primary or recurrent), 
surgical treatment by WLE or MMS, number of micro-
graphic stages, type of surgical repair (primary closure, 
graft, or flap), local recurrence, distant metastasis, and fol-
low-up period (months). Patients with both primary and re-
current lesions were included. Primary disease was defined 
as the presence of tumor without previous treatment or re-
cent tumor excision with histologically positive margins. 
Recurrent disease was defined as that occurring within or 
juxtaposed to the previous surgical excision site ≥6 months 
after the initial excision. Histological confirmation of DFSP 
was done before WLE or MMS in all patients, and all tu-
mors were stained for CD34. Patients were contacted to 
evaluate the surgical sites for recurrence. Data on recur-
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AGexpdgf4 primers according to the methods of Greco, et 
al.10 To detect the presence of COL1A1-PDGFB fusion 
transcripts, polymerase chain reaction (PCR) was carried 
out using 17 COL1A1 forward primers and a specific 
PDGFB reverse primer, as presented in Table 1. Seventeen 
COL1A1 forward primers were designed for COL1A1 ex-
ons 5, 8, 11, 15, 17, 20, 23, 26, 27, 32, 35, 38, 40, 42, 44, 
46, and 49, and these primers were considered sufficient to 
span the various breakpoints within the region encoding the 
alpha-helical domain of the COL1A1 polypeptide. The 
PCR products were directly sequenced using an Applied 
Biosystems 373A automated DNA sequencer to identify 
the breakpoints.
Statistical analysis
Associations between the clinical, histopathological, and ge-
netic aspects were assessed using a χ2 test and Fisher’s ex-
act test. The significance level was set at 5%. All tests were 
performed using a statistical software package (SPSS, Ver-
sion 18.0, SPSS Inc., Chicago, IL, USA).
Table 1. Primers for COL1A1 and PDGFB
Primer set Exon Sequence 5’ to 3’ 
COL1A1   
  (forward) 
    1   5 GCCGAGATGGCATCCCTGG 
    2   8 CCCTGGTGAGCCTGGCGA 
    3 11 TCAGGGTGCTCGAGGATTGC 
    4 15 GGTGCTCGTGGAAATGATGG 
    5 17 AAGGTCCCCAGGGTGTGCG 
    6 20 AACCTGGTGCTCCTGGCAGC 
    7 23 AAGCTGGTCGTCCCGGTGAAGC 
    8 26 AAGGCTGGAGAGCGAGGTGTTC 
    9 27 TGCTGGCAAAGATGGAGAGG 
    10 32 TAGAACGTGGTGCAGCTGGTCTTC 
    11 35 TCCCACTGGAGCTCGTGG 
    12 38 TGCTCCTGGAGCCAAAGGTGC 
    13 40 TGCTGGCGAGAAAGGATCCCCTG 
    14 42 AAGGTCCCTCTGGAGCAAGT 
    15 43 TGGCAAGAGTGGTGATCGTGG 
    16 46 TGGCTTCTCTGGCCTCCAGGG 
    17 49 ACCTCAAGAGAAGGCTCACGATGG 
PDGFB 
  (reverse)
    1   2 ATCAAAGGAGCGGATCGAGTGGTC 
COL1A1, collagen type I alpha 1; PDGFB, platelet-derived growth factor 
beta.
Annealing temperature: 65.7°C.
Table 2. Clinicopathologic Characteristics of 37 DFSP Pa-
tients
Clinicopathologic variables Number of patients (%)
Total cases    37
Follow-up months
    Mean (range)    33 (6‒79)
Age (yrs)
    Mean (range) 37.4 (3‒74)
Gender
    Male/female    19 (51.3)/18 (48.6)
Location
    Head and neck      4 (10.8)
    Upper extremity      8 (21.6)
    Lower extremity      9 (24.3)
    Trunk    16 (43.2)
Size (pre-op)
    Median size (cm2, range)   6.2 (1.2‒44.2)
Size (post-op)
    Median size (cm2, range) 19.6 (2.5‒122.7)
Histology
    Conventional    28 (75.7)
    Fibrosarcomatous      5 (13.5)
    Myxoid      2 (5.4)
    Giant cell fibroblastoma      2 (5.4)
Primary/recurred
    Primary (de novo) tumor    24 (64.9)
    Recurred tumor    13 (35.1)
Surgical Method
    MMS    34 (91.9)
    WLE      3 (8.1)
Mohs layer
    1    11 (32.4)
    2    19 (54.9)
    3      3 (8.8)
    4      1 (2.9)
Repair
    Primary closure    23 (62.2)
    Flap      9 (24.3)
    Graft      3 (8.1)
    Secondary intention      2 (5.4)
Subcutaneous infiltration of tumor
    Yes    19 (51.4)
    No    18 (48.6)
Muscle infiltration of tumor
    Yes      8 (21.6)
    No    29 (78.4)
Recurrence
    Yes      2 (5.4)
    No    35 (94.6)
MMS, Mohs micrographic surgery; WLE, wide local excision; DFSP, der-
matofibrosarcoma protuberans.
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showed positive margins. 
Histopathological findings
H&E-stained slides were reviewed. The tumors were catego-
rized histologically as conventional DFSP versus special 
variants: giant cell fibroblastoma (GCF, combination of 
spindle cell patterns with myxoid areas, multinucleated giant 
cells, and distinctive sinusoid-like spaces), myxoid (DFSP 
with >50% myxoid stromal changes), or the presence of ar-
eas with high-grade fibrosarcomatous changes (DFSP-FS) 
in at least 5% of the lesion. The high-grade fibrosarcoma-
tous areas could be recognized by fascicular, herringbone 
growth patterns at low power and unusually increased cel-
lularity and cytologic atypia.12 Conventional DFSP (28 cases, 
75.7%) was the most common histologic type in our study. 
In 5 cases (13.5%), storiform pattern was admixed with high-
grade cellular areas to form a herringbone appearance which 
is consistent with DFSP-FS. There were 2 cases (5.4%) of 
myxoid DFSP and 2 cases (5.4%) of GCF. In 19 cases 
(51.4%), tumors showed tentacle-like projections into the 
underlying subcutaneous tissue, resulting in a honeycomb 
appearance. In 8 cases (21.6%), the tumor showed muscle 
infiltration. Compared with conventional DFSP, DFSP-FS 
showed significant subcutaneous (p<0.05) and muscle infil-
trations (p<0.001). The histologic subtype of the 2 patients 
who showed recurrence in our study was DFSP-FS. The re-
currence rate of DFSP-FS was significantly higher compared 
to other types of DFSP (p=0.015).
Immunohistochemistry
All of the tumors expressed CD34. In our study, all DFSP-
FS demonstrated high CD34 expression. However, there 
was no significant difference in CD34 expression compared 
with conventional DFSP. Ki-67 and p53 were expressed in 
27.3% and 24.2% of cases, respectively, and were more 
RESULTS
 
Clinicopathological findings
In total, 37 cases of DFSP were reviewed. The clinicopath-
ological features are summarized in Table 2. The mean age 
at diagnosis was 37.4 years, and the ratio of males to fe-
males was 1.1:1. The most common tumor location was the 
trunk (43.2%), followed by the extremities and the head 
and neck. Of the 37 cases analysed, 24 cases (64.9%) were 
de novo neoplasms and 13 (35.1%) were recurred cases. All 
the recurred cases were previously treated by simple exci-
sion or WLE. The median preoperative tumor size was 6.2 
cm2. All patients were treated primarily by surgery: 34 
(91.9%) cases by MMS and 3 (8.1%) by WLE. One patient 
with recurred DFSP was treated with imatinib mesylate as a 
neoadjuvant therapy before MMS, because of multiple re-
currences and the location of the tumor, which was on the 
finger web.11 Imatinib 400 mg twice a day for 3 months fol-
lowed by reduced dose, 400 mg once a day for 2 months, 
was prescribed. MMS was performed after reduction of tu-
mor size with Imatinib treatment. For those tumors that 
were treated with MMS, a mean of 1.8 Mohs stages were 
required. The median postsurgical defect size was 19.6 cm2. 
Postsurgical defects were reconstructed by primary closure 
in 23 cases (62.2%), covered by flaps in 9 cases (24.3%), 
grafts in 3 cases (8.1%), and secondary intention healing in 
2 cases (5.4%). None of our patients were treated with ra-
diotherapy after surgery. The mean follow-up period was 
33 months (range 6–79), and 2 patients (1 MMS and 1 
WLE) demonstrated local recurrence during follow-up. 
None of the patients showed distant metastasis. Of the 34 
cases of DFSP treated by MMS, 1 case recurred. The per-
manent pathological slides and CD34 stain of the MMS 
specimens of this patient were reviewed afterwards, which 
Table 3. Immunohistochemical Findings of Conventional DFSP and DFSP-FS
n (%) DFSP (%) DFSP-FS (%) p value
CD34 NS
    Low 12 (36.4) 12 (42.9) 0 (0)
    High 21 (63.6) 16 (58.1) 5 (100)
Ki-67 0.003
    Negative 24 (72.7) 24 (85.7) 0 (0)
    Positive   9 (27.3)   4 (14.3) 5 (100)
p53 0.023
    Negative 25 (75.8) 24 (85.7) 1 (20)
    Positive   8 (24.2)   4 (14.3) 4 (80)
DFSP, dermatofibrosarcoma protuberans; DFSP-FS, dermatofibrosarcoma protuberans-fibrosarcomatous variant.
CD34, high (≥50%) or low (<50%) according to percentage of immunoreactive cells; Ki-67 and p53, positive (>5% immunoreactive nuclei) or negative (<5%).
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L1A1 (from exon 5 to exon 49) and exon 2 of PDGFB. The 
COL1A1 breakpoints occurred at the following exons: 25 
(two cases), 29 (two cases), 32 (two cases), 34 (five cases), 
43 (one case), and 45 (two cases). No association was found 
among the different COL1A1-PDGFB fusion transcripts, 
histological subtypes and clinical features. A schematic rep-
resentation of our findings is depicted in Fig. 1. 
DISCUSSION
Since DFSP is an uncommon tumor, it has not been well-
studied in Asia, and there are few reports in the literature.8,13-15 
Therefore, we analysed the clinical, pathological, and ge-
prevalent in DFSP-FS than in conventional DFSP (Table 3). 
All 5 cases of DFSP-FS showed positive immunostaining 
for Ki-67, compared with 14.3% positivity in conventional 
DFSP (p=0.003). For p53, 80% of the cases in DFSP-FS 
stained positive, compared with 14.3% in conventional 
DFSP (p=0.023).
Analysis of the COL1A1-PDGFB fusion transcripts
In 16 of 37 cases, reverse transcriptase-PCR analysis was 
performed. Only 16 cases out of 37 contained human RNA 
of sufficient quality/quantity for PCR amplification. The CO-
L1A1-PDGFB fusion gene was expressed in 14 (87.5%) cas-
es. Sequencing analysis of the different fusion types revealed 
a high variety of combinations among several exons of CO-
Fig. 1. (A) Schematic presentation of variable positions of collagen type I alpha 1 (COL1A1) breakpoints in the COL1A1-platelet-derived 
growth factor beta (PDGFB) fusion gene. (B) Some examples of the COL1A1-PDGFB fusion transcript. DFSP, dermatofibrosarcoma protu-
berans; DFSP-FS, dermatofibrosarcoma protuberans-fibrosarcomatous variant.
COL1A1 exon 29
COL1A1 exon 32
PDGFB exon 2
PDGFB exon 2
1 31A 4 62 5 7
PDGFBExons
COL1A1Exons
DFSP
DFSP-FS
Giant cell fibroblastoma
A
B
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87.5% of cases. This percentage is similar to that found by 
Takahira, et al.21 As reported by other groups,19 we did not 
find a significant association between the presence of dif-
ferent breakpoints and the histologic variants of DFSP or 
their clinical characteristics.
Advances in the understanding of molecular mechanisms 
of DFSP have resulted in the implementation of targeted 
therapy against DFSP based on PDGFR inhibition. Imatinib 
mesylate is a tyrosine kinase inhibitor rationally developed 
to target BCR/ABL, KIT, FMS (receptor for colony stimu-
lating factor 1), ARG (an ABL-related gene), and PDGFR 
alpha and beta. It was found to be the first effective system-
ic therapy for DFSP. Many studies suggested the usefulness 
of imatinib in metastatic and locally advanced DFSP. Kérob, 
et al.22 reported 25 cases of unresectable DFSP treated in a 
phase II trial with preoperative imatinib at a dose of 600 mg 
daily for two months, and indicated that some DFSP pa-
tients who were initially evaluated as unresectable/meta-
static or necessitating mutilating surgery had resectable tu-
mors after imatinib therapy. Similarly, we experienced one 
patient who required neoadjuvant therapy with imatinib to 
reduce tumor size. The tumor was located at the finger web, 
where WLE was impossible.
Although WLE has historically been the treatment of 
choice for DFSP, MMS is another favorable option, as it of-
fers the advantage of immediate microscopic examination of 
the entire surgical margin after excision, which allows for 
precise tumor mapping. The main purpose of MMS in DFSP 
is to minimize surgical margins, resulting in less complicated 
reconstruction with smaller postsurgical defects without 
jeopardizing the oncologic resection.7,23,24 A meta-analysis by 
Paradisi, et al.7 of 463 patients with DFSP treated with MMS 
showed recurrence in 6 cases (1.2%), confirming that the 
treatment of choice for DFSP is MMS.7,8,25 Our study also 
supports the use of MMS in DFSP. Thirty-four cases were 
successfully treated, with only one patient (2.9%) showing 
recurrence during follow-up. Also, the COL1A1-PDGFB 
fusion transcript was observed in 87.5% of patients; there-
fore, COL1A1-PDGFB may be a useful and accurate tool 
for diagnosing DFSP in Koreans. 
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DFSP is an uncommon tumor, with an overall incidence 
of 0.8 to 5 per million.16 It is most frequently diagnosed in 
people between 30 and 50 years of age, which is consistent 
with our results.16 It is found in similar frequencies in men 
and women, with only a slight male predominance.2 Typi-
cally, the tumor initially presents as a slowly growing indu-
rated plaque that can eventually transform into a violaceous 
to red-brown painless nodule, most commonly on the trunk 
or upper limbs and less often on the head and neck.8 Kim, 
et al.15 previously reported 65 cases of DFSP in Koreans, 
which showed similar age range and site distribution. 
DFSP has a number of well-described histological vari-
ants. Most commonly, conventional DFSP demonstrates pro-
liferation of dermal spindle cells that infiltrate into the subcu-
taneous fat. These proliferations are made up of monotonous 
cells with little pleomorphism and a low mitotic index. The 
spindle cells in the dermis are arranged in storiform pattern, 
and the infiltrating portion of the tumor is characterized as 
honeycomb in appearance. DFSP-FS is an another variant 
which exhibits areas of classic low-grade DFSP with inter-
spersed foci of significant cellular atypia and increased mito-
ses, and it has been estimated that 7% to 16% of tumors have 
areas of fibrosarcomatous change.17 Although some authors 
have reported that these tumors behave more aggressively 
and are associated with a higher frequency of recurrence and 
a greater risk of metastasis,12,17 several articles reported that 
the prognosis of DFSP with fibrosarcomatous transformation 
has a prognosis similar to that of conventional DFSP.18,19 In 
our study, 13.5% of cases were DFSP-FS. Compared with 
other variants, fibrosarcomatous DFSP in our study showed a 
higher frequency of tumor infiltration into the subcutaneous 
fat and muscle. Also, the recurrence rate of DFSP-FS was 
significantly higher compared to other types. 
DFSP is characterized by the presence of a distinctive, re-
ciprocal rearrangement of chromosomes 17 and 22 in the 
form of a translocation t(17;22)(q22;q13) or supernumerary 
ring chromosomes containing material from chromosomal 
regions of 17q22 and 22q13.20 This rearrangement leads to 
the fusion of COL1A1, which is localized on 17q22, to the 
PDGFB, which is localized on 22q13. Confirmation of the 
presence of the COL1A1-PDGFB fusion gene is a useful 
tool to identify patients who may be candidates for treatment 
with imatinib and for the differential diagnosis of DFSP with 
other CD34+ tumors or CD34-DFSP. In the present study, 
we indeed identified COL1A1-PDGFB fusion transcripts in 
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